Prof. Dr. Meral Beksaç

ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: ICARIA-MM SUBGROUP ANALYSIS

Hematology Transfusion and Cell Therapy, 2020

DOI 10.1016/j.htct.2020.10.440 7 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in patients with myeloproliferative neoplasm.

Journal of Clinical Oncology, 2020

DOI 10.1200/jco.2020.38.15_suppl.e19536 Source : OpenAlex

EFFICACY AND SAFETY OF CARFILZOMIB, DEXAMETHASONE, DARATUMUMAB TWICE-WEEKLY AT 56 MG/M2 AND ONCE-WEEKLY AT 70 MG/M2 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CROSS-STUDY COMPARISON OF CANDOR AND MMY1001

Hematology Transfusion and Cell Therapy, 2020

DOI 10.1016/j.htct.2020.10.431 Texte intégral en libre accèsSource : OpenAlex

MM-040: Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies

Clinical Lymphoma Myeloma & Leukemia, 2020

DOI 10.1016/s2152-2650(20)30917-4 Source : OpenAlex

Bortezomib-Based Transplantation and Consolidation Therapy Followed by Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma

SSRN Electronic Journal, 2020

DOI 10.2139/ssrn.3516132 Texte intégral en libre accèsSource : OpenAlex

Myelodisplastik Sendromda Allojeneik Kök Hücre Nakli

DergiPark (Istanbul University), 2020

Source : OpenAlex

Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable ≥Vgpr Responses Among Immunomodulatory / Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

Clinical Lymphoma Myeloma & Leukemia, 2019

DOI 10.1016/j.clml.2019.09.402 2 citations (OpenAlex) Source : OpenAlex

Fetal Cell Microchimerism; Normal and Immunocompromised Gestations in Mice

Fetal and Pediatric Pathology, 2019

DOI 10.1080/15513815.2019.1651803 PMID 31436120 3 citations (Europe PMC) Source : OpenAlex

A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma

Expert Opinion on Drug Safety, 2019

DOI 10.1080/14740338.2019.1615051 PMID 31070945 30 citations (Europe PMC) Source : ORCID

A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis

Leukemia and Lymphoma, 2019

DOI 10.1080/10428194.2018.1466392 PMID 30407092 6 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM)

Journal of Clinical Oncology, 2019

DOI 10.1200/jco.2019.37.15_suppl.8004 17 citations (OpenAlex) Source : ORCID

A retrospective single center experience with the generic of lenalidomide Rivelime® compared with original patented drug Revlimid®

American Journal of Hematology, 2019

Source : ORCID

ANTI-PD-1 Treatment in a Family with Constitutional Mismatch Repair Deficiency Syndrome with Multiple Cancers from Turkey. Is Cancer Immunoprevention with Checkpoint Inhibitors HAS a Role in CASES with Homozygous Mutationis

Blood, 2019

DOI 10.1182/blood-2019-130102 2 citations (OpenAlex) Source : ORCID

Analysis of outcomes in patients with myeloma who had a second allohct EITHER for disease relapse or graft failure: AN EBMT CMWP study

Bone Marrow Transplantation, 2019

Source : ORCID

Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?

Journal of Clinical Oncology, 2019

DOI 10.1200/jco.2019.37.15_suppl.e19524 Source : ORCID

Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased os in myeloma patients after ASCT?

Bone Marrow Transplantation, 2019

Source : ORCID

Clonal plasma cell detection by high sensitive flow cytometry in aphaeresis product is poor prognostic and not increased by use of plerixafor alone

Bone Marrow Transplantation, 2019

Source : ORCID

Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT

Blood, 2019

DOI 10.1182/blood-2019-128795 2 citations (OpenAlex) Texte intégral en libre accèsSource : ORCID

Depth of Response and Response Kinetics in the Icaria-MM Study of Isatuximab with Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Blood, 2019

DOI 10.1182/blood-2019-129840 6 citations (OpenAlex) Source : ORCID

Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis

Blood, 2019

DOI 10.1182/blood-2019-127651 3 citations (OpenAlex) Source : ORCID

Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR

Journal of Clinical Oncology, 2019

DOI 10.1200/jco.2019.37.15_suppl.8040 2 citations (OpenAlex) Source : ORCID

Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial

Clinical Lymphoma Myeloma and Leukemia, 2019

DOI 10.1016/j.clml.2019.09.022 8 citations (OpenAlex) Source : ORCID

Evaluation of chemokine receptor-4 expression by 68ga – Pentixafor PET/CT in patients with multiple myeloma,Multipl myelomalı hastalarda kemokin reseptör-4 ekspresyonunun ga-68 pentiksafor PET/BT ile değerlendirilmesi

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2019

DOI 10.4999/uhod.193630 5 citations (OpenAlex) Source : ORCID

Haploidentical stem cell transplantation may be an option for hematological malignancies in urgent conditions

Bone Marrow Transplantation, 2019

Source : ORCID

Hepatitis B reactivation rate and fate among multiple myeloma patients receiving regimens containing lenalidomide and/or bortezomib,Lenalidomid ve/veya bortezomib içeren tedavi alan multipl myelom hastalarında hepatit b reaktivasyon sıklığı ve sonuçları

Turkish Journal of Hematology, 2019

DOI 10.4274/tjh.galenos.2019.2019.0103 PMID 31368290 9 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Influence of Conditioning Regimens with Total Body Irradiation (TBI) on Graft Versus Host Disease and Graft Versus Leukemia Effect Following Donor Lymphocyte Infusions (DLI)

Biology of Blood and Marrow Transplantation, 2019

DOI 10.1016/j.bbmt.2018.12.318 Texte intégral en libre accèsSource : ORCID

Insights on Multiple Myeloma Treatment Strategies

HemaSphere, 2019

DOI 10.1097/hs9.0000000000000163 PMID 31723802 34 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Is mobilization with chemotherapy effect response in the multiple myeloma?

Bone Marrow Transplantation, 2019

Source : ORCID

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

The Lancet, 2019

DOI 10.1016/s0140-6736(19)32556-5 PMID 31735560 489 citations (Europe PMC) Source : ORCID

Ixazomib maintenance therapy following autologous stem cell transplantation significantly prolongs progression-free survival in patients with newly diagnosed Multiple Myeloma: phase 3 TOURMALINE-MM3 trial

Oncology Research and Treatment, 2019

Source : ORCID

Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

Blood, 2019

DOI 10.1182/blood-2019-128750 1 citation (OpenAlex) Source : ORCID

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Biology of Blood and Marrow Transplantation, 2019

DOI 10.1016/j.bbmt.2018.12.087 5 citations (OpenAlex) Texte intégral en libre accèsSource : ORCID

Maintenance Therapy with the Oral Proteasome Inhibitor Ixazomib Significantly Prolongs Progression-Free Survival Post-Autologous Stem Cell Transplantation Vs Placebo in Patients with Newly Diagnosed Multiple Myeloma: Phase 3 TOURMALINE-MM3 Trial

British Journal of Haematology, 2019

Source : ORCID

Management of adverse events (AEs) observed in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (MM)

Clinical Lymphoma Myeloma and Leukemia, 2019

DOI 10.1016/j.clml.2019.09.481 Source : ORCID

Modulation of NK, T, & B cell subpopulations by Pomalidomide predicts favorable progression-free survival (PFS): Results from a large randomized clinical trial in relapsed/refractory myeloma

Clinical Lymphoma Myeloma and Leukemia, 2019

DOI 10.1016/j.clml.2019.09.279 Source : ORCID

Multiple myeloma treatment in real-world clinical practice: A focus on induction regimens prior to autologous stem cell transplantation from the prospective, multinational, non-interventional emmos study

Bone Marrow Transplantation, 2019

Source : ORCID

Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation

Clinical Lymphoma Myeloma and Leukemia, 2019

DOI 10.1016/j.clml.2019.09.329 Source : ORCID

Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs

Blood, 2019

DOI 10.1182/blood-2019-127541 1 citation (OpenAlex) Source : ORCID

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

The Lancet, 2019

DOI 10.1016/s0140-6736(18)33003-4 PMID 30545780 185 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma

PET Clinics, 2019

DOI 10.1016/j.cpet.2019.03.009 PMID 31084776 6 citations (Europe PMC) Source : ORCID

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

The Lancet Oncology, 2019

DOI 10.1016/s1470-2045(19)30152-4 PMID 31097405 318 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation

Journal of Clinical Oncology, 2019

DOI 10.1200/jco.2019.37.15_suppl.e19532 Source : ORCID

Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma

Leukemia and Lymphoma, 2019

DOI 10.1080/10428194.2018.1459609 PMID 29741423 10 citations (Europe PMC) Source : ORCID

Protocol for an International, MultiCentre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma (INTEGRATE)

Blood, 2019

DOI 10.1182/blood-2019-122732 Source : ORCID

Results of a single center experience: An attempt to augment conditioning regimen in first autologous stem cell transplantation

Bone Marrow Transplantation, 2019

Source : ORCID

Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients - the Diadem Study from the Chronic Malignancies Working Party of the EBMT

Blood, 2019

DOI 10.1182/blood-2019-127238 2 citations (OpenAlex) Source : ORCID

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients

Leukemia and Lymphoma, 2019

DOI 10.1080/10428194.2018.1473574 PMID 29965787 28 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

THE EFFECT OF PREDICTED INDIRECTLY RECOGNIZABLE HLA EPITOPES PRESENTED BY HLA-CLASS II MOLECULES ON 1 ANTIGEN/ALELLE MISMATCHED UNRELATED HSCT: A SINGLE CENTER EXPERIENCE

HLA, 2019

Source : ORCID

Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017

Blood, 2019

DOI 10.1182/blood-2019-127166 3 citations (OpenAlex) Source : ORCID

Trial in Progress: Once-Weekly vs Twice-Weekly Carfilzomib (K) Dosing in Combination with Lenalidomide (R) and Dexamethasone (d) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Clinical Lymphoma Myeloma and Leukemia, 2019

DOI 10.1016/j.clml.2019.07.324 Source : ORCID